About Us

VeriPhy LLC was founded in 2026 to address a long-standing gap in cardiovascular diagnostics: the lack of standardized, verifiable execution of physiologic maneuvers such as Valsalva.

In current practice, the Valsalva maneuver is widely used but inconsistently performed, introducing variability into diagnostic interpretation. VeriPhy was established to bring structure, measurement, and repeatability to this critical component of cardiovascular testing.

The company’s core technology, ValCore™, transforms the maneuver into a guided, measurable process through real-time pressure and duration feedback. Supporting this system, ValSet™ provides a standardized, single-use patient interface compatible with both ValCore and existing manual manometers, enabling consistent implementation across clinical environments.
VeriPhy has three pending patents related to physiologic maneuver standardization and verification systems, with FDA pathway activities currently in progress. Ongoing research is underway to evaluate the clinical impact of guided Valsalva execution using ValCore.

VeriPhy was selected to participate in the 2026 American Society of Echocardiography (ASE) Accelerator program, supporting early-stage innovation in cardiovascular imaging.

VeriPhy was founded by Judith Buckland, MBA, RDCS, FASE, who brings over 35 years of experience in cardiovascular diagnostic imaging, accreditation, and quality improvement. Her work has focused on reducing variability in imaging and improving the reliability of clinical data across healthcare systems.

VeriPhy’s mission is to establish a new standard for physiologic maneuver performance—shifting from subjective instruction to measurable, reproducible execution.